Govt stops central allocation of Remdesivir to states as supply improves

The government has also increased the number of plants producing Remdesivir from just 20 to 60 plants within a month

Remdesivir, coronavirus, covid-19, drugs, medicine, health
Press Trust of India New Delhi
2 min read Last Updated : May 29 2021 | 4:33 PM IST

The Centre has stopped allocation of antiviral drug Remdesivir to states as the supply of the critical medication has surpassed the demand, Union Minister Mansukh L Mandaviya said on Saturday.

"Now the country has enough #Remdesivir as the supply is much more than the demand. So we have decided to DISCONTINUE the Central Allocation of Remdesivir to States," Mandaviya said in a tweet.

The Minister of State for Chemicals and Fertilisers noted that the supply of the drug, which is being used to treat COVID-19, has been ramped up over ten times from just 33,000 vials a day on April 11, 2021 to 3,50,000 vials per day currently.

The government has also increased the number of plants producing Remdesivir from just 20 to 60 plants within a month, he added.

Besides, the Centre has decided to procure 50 lakh vials of Remdesivir to maintain it as a strategic stock for emergency requirement, Mandaviya said.

"But I have also directed @nppa_india & @CDSCO_INDIA_INF to continuously monitor the availability of Remdesivir in the country," he noted.

In order to improve supply, the government has already waived customs duty on Remdesivir, its raw materials and other components used in making the antiviral drug in order to help augment domestic availability and reduce the cost of the injection.

On April 11, in view of increased demand for Remdesivir, the Centre banned the export of the injection and its active pharmaceutical ingredients (APIs) till the situation improves.

Various drug companies have also cut the prices of Remdesivir injection following intervention of the government.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusRemdesivirCoronavirus Tests

First Published: May 29 2021 | 4:31 PM IST

Next Story